这是一篇来自已证抗体库的有关人类 HLA-A (HLA-A) 的综述,是根据128篇发表使用所有方法的文章归纳的。这综述旨在帮助来邦网的访客找到最适合HLA-A 抗体。
HLA-A 同义词: HLAA

BioLegend
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类; 1:50
BioLegendHLA-A抗体(Biolegend, BB7.2)被用于被用于流式细胞仪在人类样本上浓度为1:50. Sci Signal (2020) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 1:75; 图 2b
BioLegendHLA-A抗体(BioLegend, W6/32)被用于被用于流式细胞仪在人类样本上浓度为1:75 (图 2b). Nature (2020) ncbi
小鼠 单克隆(28-8-6)
BioLegendHLA-A抗体(BioLegend, 28-8-6)被用于. Nature (2020) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 1:100; 图 s20c
BioLegendHLA-A抗体(Biolegend, 311403)被用于被用于流式细胞仪在人类样本上浓度为1:100 (图 s20c). Nat Commun (2020) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 2e
BioLegendHLA-A抗体(Biolegend, 311413)被用于被用于流式细胞仪在人类样本上 (图 2e). Stem Cell Res Ther (2020) ncbi
小鼠 单克隆(SF1-1.1)
  • 流式细胞仪; 小鼠; 1:100; 图 5e
BioLegendHLA-A抗体(BioLegend, 116608)被用于被用于流式细胞仪在小鼠样本上浓度为1:100 (图 5e). Nature (2019) ncbi
小鼠 单克隆(28-14-8)
  • 流式细胞仪; 小鼠; 1:100; 图 e9c
BioLegendHLA-A抗体(BioLegend, 114507)被用于被用于流式细胞仪在小鼠样本上浓度为1:100 (图 e9c). Nature (2019) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类
BioLegendHLA-A抗体(BioLegend, W6/32)被用于被用于流式细胞仪在人类样本上. JCI Insight (2019) ncbi
小鼠 单克隆(28-14-8)
  • 流式细胞仪; 小鼠; 图 3h
BioLegendHLA-A抗体(Biolegend, 114507)被用于被用于流式细胞仪在小鼠样本上 (图 3h). Oncoimmunology (2019) ncbi
小鼠 单克隆(28-8-6)
  • mass cytometry; 小鼠; 图 3, s2
BioLegendHLA-A抗体(Biolegend, 114602)被用于被用于mass cytometry在小鼠样本上 (图 3, s2). Science (2019) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 小鼠; 图 s5b
BioLegendHLA-A抗体(BioLegend, 311426)被用于被用于流式细胞仪在小鼠样本上 (图 s5b). Nat Immunol (2019) ncbi
小鼠 单克隆(W6/32)
  • 抑制或激活实验; 人类; 10 ug/ml; 图 4i
BioLegendHLA-A抗体(Biolegend, 311427)被用于被用于抑制或激活实验在人类样本上浓度为10 ug/ml (图 4i). Cancer Cell (2019) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 s8
BioLegendHLA-A抗体(BioLegend, W6/32)被用于被用于流式细胞仪在人类样本上 (图 s8). Nat Commun (2019) ncbi
小鼠 单克隆(28-14-8)
  • 流式细胞仪; 小鼠; 图 2d
BioLegendHLA-A抗体(BioLegend, 28-14-8)被用于被用于流式细胞仪在小鼠样本上 (图 2d). PLoS ONE (2018) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 3
BioLegendHLA-A抗体(BioLegend, 311410)被用于被用于流式细胞仪在人类样本上 (图 3). J Virol (2018) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 5a
BioLegendHLA-A抗体(Biolegend, 311425)被用于被用于流式细胞仪在人类样本上 (图 5a). Stem Cells Transl Med (2018) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 s1
BioLegendHLA-A抗体(Biolegend, W6/32)被用于被用于流式细胞仪在人类样本上 (图 s1). JCI Insight (2018) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 2l
BioLegendHLA-A抗体(BioLegend, 311426)被用于被用于流式细胞仪在人类样本上 (图 2l). Cancer Res (2018) ncbi
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类; 图 3c
BioLegendHLA-A抗体(Biolegend, 343317)被用于被用于流式细胞仪在人类样本上 (图 3c). J Virol (2018) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 1:50; 图 2a
BioLegendHLA-A抗体(BioLegend, W6/32)被用于被用于流式细胞仪在人类样本上浓度为1:50 (图 2a). Nat Immunol (2018) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 5b
BioLegendHLA-A抗体(BioLegend, w6/32)被用于被用于流式细胞仪在人类样本上 (图 5b). J Virol (2018) ncbi
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类; 图 1a, 6a
BioLegendHLA-A抗体(BioLegend, BB7.2)被用于被用于流式细胞仪在人类样本上 (图 1a, 6a). J Virol (2018) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 s1b
BioLegendHLA-A抗体(BioLegend, W6/32)被用于被用于流式细胞仪在人类样本上 (图 s1b). Nature (2017) ncbi
小鼠 单克隆(W6/32)
  • 抑制或激活实验; 人类
BioLegendHLA-A抗体(BioLegend, w6/32)被用于被用于抑制或激活实验在人类样本上. J Immunol (2017) ncbi
小鼠 单克隆(W6/32)
  • 免疫细胞化学; 人类; 1:500; 图 1a
BioLegendHLA-A抗体(BioLegend, W6/32)被用于被用于免疫细胞化学在人类样本上浓度为1:500 (图 1a). J Cell Sci (2017) ncbi
小鼠 单克隆(28-8-6)
  • 免疫组化; 小鼠; 图 s3c
BioLegendHLA-A抗体(Biolegend, 114603)被用于被用于免疫组化在小鼠样本上 (图 s3c). Cell Stem Cell (2017) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 e6a
BioLegendHLA-A抗体(BioLegend, W6/32)被用于被用于流式细胞仪在人类样本上 (图 e6a). Nature (2016) ncbi
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类; 图 2e
BioLegendHLA-A抗体(BioLegend, BB7.2)被用于被用于流式细胞仪在人类样本上 (图 2e). J Immunol (2016) ncbi
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类; 图 3e, 3f
BioLegendHLA-A抗体(BioLegend, BB7.2)被用于被用于流式细胞仪在人类样本上 (图 3e, 3f). Proc Natl Acad Sci U S A (2016) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 3e, 3f
BioLegendHLA-A抗体(BioLegend, W6/32)被用于被用于流式细胞仪在人类样本上 (图 3e, 3f). Proc Natl Acad Sci U S A (2016) ncbi
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类; 图 2
BioLegendHLA-A抗体(Biolegend, BB7.2)被用于被用于流式细胞仪在人类样本上 (图 2). Sci Rep (2016) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类
BioLegendHLA-A抗体(BioLegend, W6/32)被用于被用于流式细胞仪在人类样本上. J Exp Med (2016) ncbi
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类; 图 s1
BioLegendHLA-A抗体(BioLegend, BB7.2)被用于被用于流式细胞仪在人类样本上 (图 s1). J Clin Invest (2016) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 1a
BioLegendHLA-A抗体(BioLegend, W6/32)被用于被用于流式细胞仪在人类样本上 (图 1a). J Immunol (2016) ncbi
小鼠 单克隆(SF1-1.1)
  • 流式细胞仪; 小鼠; 图 1a
BioLegendHLA-A抗体(BioLegend, SF 1-1.1)被用于被用于流式细胞仪在小鼠样本上 (图 1a). Cancer Immunol Immunother (2016) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 s2
BioLegendHLA-A抗体(Biolegend, W6/32)被用于被用于流式细胞仪在人类样本上 (图 s2). Cell Death Dis (2016) ncbi
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类; 图 5a
BioLegendHLA-A抗体(Biolegend, BB7.2)被用于被用于流式细胞仪在人类样本上 (图 5a). J Immunol (2016) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 3c
BioLegendHLA-A抗体(Biolegend, W6/32)被用于被用于流式细胞仪在人类样本上 (图 3c). J Immunol (2016) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 表 1
BioLegendHLA-A抗体(BioLegend, W6/32)被用于被用于流式细胞仪在人类样本上 (表 1). J Immunol (2016) ncbi
小鼠 单克隆(28-8-6)
  • 流式细胞仪; 小鼠; 图 2
BioLegendHLA-A抗体(Biolegend, 114612)被用于被用于流式细胞仪在小鼠样本上 (图 2). Nat Immunol (2016) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 s6b
BioLegendHLA-A抗体(BioLegend, W6/32)被用于被用于流式细胞仪在人类样本上 (图 s6b). Oncotarget (2016) ncbi
小鼠 单克隆(28-14-8)
  • 流式细胞仪; 小鼠; 1:200; 图 s1
BioLegendHLA-A抗体(BioLegend, 28-14-8)被用于被用于流式细胞仪在小鼠样本上浓度为1:200 (图 s1). Nat Commun (2016) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 1:100; 图 2
BioLegendHLA-A抗体(Biolegend, W6/32)被用于被用于流式细胞仪在人类样本上浓度为1:100 (图 2). Nat Commun (2016) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 5
BioLegendHLA-A抗体(Biolegend, 311404)被用于被用于流式细胞仪在人类样本上 (图 5). Br J Cancer (2015) ncbi
小鼠 单克隆(SF1-1.1)
  • 流式细胞仪; 小鼠; 图 2c
BioLegendHLA-A抗体(Biolegend, SF1-1.1)被用于被用于流式细胞仪在小鼠样本上 (图 2c). Transpl Immunol (2015) ncbi
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类; 图 2
BioLegendHLA-A抗体(BioLegend, 343304)被用于被用于流式细胞仪在人类样本上 (图 2). J Biol Chem (2015) ncbi
小鼠 单克隆(28-8-6)
  • 流式细胞仪; 小鼠; 图 4d
BioLegendHLA-A抗体(BioLegend, 28-8-6)被用于被用于流式细胞仪在小鼠样本上 (图 4d). J Exp Med (2015) ncbi
小鼠 单克隆(W6/32)
  • 免疫组化; 人类; 1:50
BioLegendHLA-A抗体(Biolegend, W6/32)被用于被用于免疫组化在人类样本上浓度为1:50. Mucosal Immunol (2016) ncbi
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类; 图 5
BioLegendHLA-A抗体(Biolegend, BB7.2)被用于被用于流式细胞仪在人类样本上 (图 5). PLoS Pathog (2015) ncbi
小鼠 单克隆(BB7.2)
  • 免疫细胞化学; 人类
BioLegendHLA-A抗体(BioLegend, 343304)被用于被用于免疫细胞化学在人类样本上. Mol Med Rep (2015) ncbi
小鼠 单克隆(W6/32)
  • 其他; 人类; 图 2
BioLegendHLA-A抗体(BioLegend, 311402)被用于被用于其他在人类样本上 (图 2). J Extracell Vesicles (2015) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 表 1
BioLegendHLA-A抗体(Biolegend, W.6.32)被用于被用于流式细胞仪在人类样本上 (表 1). Cancer Immunol Immunother (2015) ncbi
小鼠 单克隆(SF1-1.1)
  • 流式细胞仪; 人类; 图 s1
BioLegendHLA-A抗体(Biolegend, 116616)被用于被用于流式细胞仪在人类样本上 (图 s1). Proc Natl Acad Sci U S A (2015) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 1
  • 免疫细胞化学; 人类; 图 3
BioLegendHLA-A抗体(BioLegend, W6/32)被用于被用于流式细胞仪在人类样本上 (图 1) 和 被用于免疫细胞化学在人类样本上 (图 3). Cancer Immunol Res (2015) ncbi
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类; 图 2
BioLegendHLA-A抗体(Biolegend, BB7.2)被用于被用于流式细胞仪在人类样本上 (图 2). Cancer Immunol Res (2015) ncbi
小鼠 单克隆(W6/32)
  • 酶联免疫吸附测定; 人类; 图 s1
BioLegendHLA-A抗体(Biolegend, 311402)被用于被用于酶联免疫吸附测定在人类样本上 (图 s1). MAbs (2015) ncbi
小鼠 单克隆(W6/32)
  • 抑制或激活实验; 人类; 15 ug/ml; 图 4
BioLegendHLA-A抗体(BioLegend, W6/32)被用于被用于抑制或激活实验在人类样本上浓度为15 ug/ml (图 4). Vaccine (2015) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 1
BioLegendHLA-A抗体(Biolegend, W6/32)被用于被用于流式细胞仪在人类样本上 (图 1). J Infect Dis (2015) ncbi
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类
BioLegendHLA-A抗体(BioLegend, BB7.2)被用于被用于流式细胞仪在人类样本上. PLoS ONE (2014) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类
BioLegendHLA-A抗体(BioLegend, W6/32)被用于被用于流式细胞仪在人类样本上. J Leukoc Biol (2014) ncbi
小鼠 单克隆(W6/32)
  • 免疫组化; 小鼠; 1:50; 图 3
BioLegendHLA-A抗体(BioLegend, 311402)被用于被用于免疫组化在小鼠样本上浓度为1:50 (图 3). Mol Cancer Res (2015) ncbi
小鼠 单克隆(BB7.2)
BioLegendHLA-A抗体(BioLegend, BB7.2)被用于. J Immunol (2014) ncbi
小鼠 单克隆(W6/32)
  • 免疫印迹; 人类; 图 2
BioLegendHLA-A抗体(BioLegend, W6/32)被用于被用于免疫印迹在人类样本上 (图 2). Gastroenterology (2014) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类
BioLegendHLA-A抗体(Biolegend, 311403)被用于被用于流式细胞仪在人类样本上. PLoS ONE (2013) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 2d
BioLegendHLA-A抗体(BioLegend, W6/32)被用于被用于流式细胞仪在人类样本上 (图 2d). J Leukoc Biol (2014) ncbi
赛默飞世尔
大鼠 单克隆(YTH862.2)
  • 流式细胞仪; 人类; 图 3e
赛默飞世尔HLA-A抗体(Invitrogen, MA1-80014)被用于被用于流式细胞仪在人类样本上 (图 3e). Breast Cancer Res (2019) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 1a
赛默飞世尔HLA-A抗体(eBioscience, W6/32)被用于被用于流式细胞仪在人类样本上 (图 1a). J Immunol (2018) ncbi
小鼠 单克隆(W6/32)
  • 抑制或激活实验; 人类; 图 s2b
赛默飞世尔HLA-A抗体(eBiosciences, w6/32)被用于被用于抑制或激活实验在人类样本上 (图 s2b). Nat Med (2018) ncbi
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类; 图 1d
  • 流式细胞仪; 小鼠; 图 3d
赛默飞世尔HLA-A抗体(eBiosciences, 17-9876-42)被用于被用于流式细胞仪在人类样本上 (图 1d) 和 被用于流式细胞仪在小鼠样本上 (图 3d). J Clin Invest (2017) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 1a
赛默飞世尔HLA-A抗体(eBiosciences, W6/32)被用于被用于流式细胞仪在人类样本上 (图 1a). Oncoimmunology (2017) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 1a
赛默飞世尔HLA-A抗体(eBioscience, W6/32)被用于被用于流式细胞仪在人类样本上 (图 1a). Eur J Pharm Biopharm (2017) ncbi
小鼠 单克隆(W6/32)
  • 免疫组化; 人类; 1:5000
赛默飞世尔HLA-A抗体(Thermo Fisher, W6/32)被用于被用于免疫组化在人类样本上浓度为1:5000. Neurology (2017) ncbi
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类; 图 1d
赛默飞世尔HLA-A抗体(eBioscience, BB7.2)被用于被用于流式细胞仪在人类样本上 (图 1d). Am J Transplant (2017) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 s9a
赛默飞世尔HLA-A抗体(eBiosciences, W6/32)被用于被用于流式细胞仪在人类样本上 (图 s9a). PLoS Pathog (2016) ncbi
小鼠 单克隆(GAP.A3)
  • 流式细胞仪; 人类; 图 2b
赛默飞世尔HLA-A抗体(eBiosciences, GAP.A3)被用于被用于流式细胞仪在人类样本上 (图 2b). J Immunol (2016) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 1
赛默飞世尔HLA-A抗体(eBioscience, W6/32)被用于被用于流式细胞仪在人类样本上 (图 1). Inflammation (2016) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 s9a
赛默飞世尔HLA-A抗体(eBiosciences, W6/32)被用于被用于流式细胞仪在人类样本上 (图 s9a). Nature (2016) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 1:50; 图 s2j
赛默飞世尔HLA-A抗体(ebioscience, W6/32)被用于被用于流式细胞仪在人类样本上浓度为1:50 (图 s2j). Nat Med (2016) ncbi
小鼠 单克隆(W6/32)
  • 免疫组化-石蜡切片; 人类; 1:5000; 图 4
赛默飞世尔HLA-A抗体(Thermo Fisher Scientific, W6/32)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:5000 (图 4). Neurology (2016) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 6
赛默飞世尔HLA-A抗体(eBioscience, clone W6/32)被用于被用于流式细胞仪在人类样本上 (图 6). Leuk Res (2014) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类
赛默飞世尔HLA-A抗体(eBioscience, W6/32)被用于被用于流式细胞仪在人类样本上. PLoS ONE (2014) ncbi
小鼠 单克隆(W6/32)
  • 免疫沉淀; 人类
  • 免疫印迹; 人类
赛默飞世尔HLA-A抗体(Thermo Fisher, MA1-19027)被用于被用于免疫沉淀在人类样本上 和 被用于免疫印迹在人类样本上. PLoS ONE (2014) ncbi
小鼠 单克隆(W6/32)
  • 免疫细胞化学; 人类
赛默飞世尔HLA-A抗体(eBiosciences, 14-9983-82)被用于被用于免疫细胞化学在人类样本上. J Biol Chem (2014) ncbi
小鼠 单克隆(W6/32)
  • 免疫印迹; 人类
赛默飞世尔HLA-A抗体(Zymed Laboratories, W6/32)被用于被用于免疫印迹在人类样本上. PLoS Pathog (2011) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类
赛默飞世尔HLA-A抗体(eBioscience, w6/32)被用于被用于流式细胞仪在人类样本上. Nat Immunol (2008) ncbi
艾博抗(上海)贸易有限公司
domestic rabbit 单克隆(EP1395Y)
  • 免疫印迹; 人类; 1:1000; 图 s2k
艾博抗(上海)贸易有限公司HLA-A抗体(Abcam, EP1395Y)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 s2k). Nature (2020) ncbi
domestic rabbit 单克隆(EPR1394Y)
  • 免疫印迹; 人类; 1:1000; 图 s2h
艾博抗(上海)贸易有限公司HLA-A抗体(Abcam, EPR1394Y)被用于被用于免疫印迹在人类样本上浓度为1:1000 (图 s2h). Nature (2020) ncbi
domestic rabbit 单克隆(EP1395Y)
  • 免疫组化-冰冻切片; 人类; 1:100; 图 s1f
艾博抗(上海)贸易有限公司HLA-A抗体(ABCAM, ab52922)被用于被用于免疫组化-冰冻切片在人类样本上浓度为1:100 (图 s1f). Nature (2020) ncbi
大鼠 单克隆(ER-HR 52)
  • 免疫组化-冰冻切片; 小鼠; 1:100; 图 4c
艾博抗(上海)贸易有限公司HLA-A抗体(Abcam, ER-HR 52)被用于被用于免疫组化-冰冻切片在小鼠样本上浓度为1:100 (图 4c). Mol Neurodegener (2018) ncbi
domestic rabbit 单克隆(EP1395Y)
  • 免疫印迹; 人类; 图 5a
艾博抗(上海)贸易有限公司HLA-A抗体(Abcam, ab52922)被用于被用于免疫印迹在人类样本上 (图 5a). Proteome Sci (2016) ncbi
domestic rabbit 单克隆(EP1395Y)
  • 免疫组化; 大鼠; 1:100; 图 5b
艾博抗(上海)贸易有限公司HLA-A抗体(Abcam, ab52922)被用于被用于免疫组化在大鼠样本上浓度为1:100 (图 5b). Sci Rep (2016) ncbi
domestic rabbit 单克隆(EP1395Y)
  • 免疫细胞化学; 人类; 1:100; 图 6a
艾博抗(上海)贸易有限公司HLA-A抗体(Abcam, EP1395Y)被用于被用于免疫细胞化学在人类样本上浓度为1:100 (图 6a). Oncotarget (2016) ncbi
大鼠 单克隆(ER-HR 52)
  • 免疫组化-冰冻切片; 小鼠; 图 5g
艾博抗(上海)贸易有限公司HLA-A抗体(Abcam, ab15681)被用于被用于免疫组化-冰冻切片在小鼠样本上 (图 5g). Sci Rep (2016) ncbi
domestic rabbit 单克隆(EP1395Y)
  • 免疫组化-石蜡切片; 人类; 1:100; 图 1
艾博抗(上海)贸易有限公司HLA-A抗体(abcam, ab52922)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:100 (图 1). PLoS ONE (2016) ncbi
domestic rabbit 单克隆(EPR1394Y)
  • 免疫组化-石蜡切片; 人类; 1:500; 表 5
艾博抗(上海)贸易有限公司HLA-A抗体(Epitomics, 2307-1)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:500 (表 5). PLoS ONE (2016) ncbi
大鼠 单克隆(ER-HR 52)
  • 免疫细胞化学; 小鼠; 1:200; 图 s8e
艾博抗(上海)贸易有限公司HLA-A抗体(Abcam, ER-HR52)被用于被用于免疫细胞化学在小鼠样本上浓度为1:200 (图 s8e). Nat Commun (2016) ncbi
大鼠 单克隆(ERMP42)
  • 免疫组化-冰冻切片; 大鼠; 1:100; 图 3
艾博抗(上海)贸易有限公司HLA-A抗体(Abcam, ab15680)被用于被用于免疫组化-冰冻切片在大鼠样本上浓度为1:100 (图 3). Exp Ther Med (2016) ncbi
domestic rabbit 单克隆(EP1395Y)
  • 免疫组化-石蜡切片; 人类; 1:250; 图 2c
艾博抗(上海)贸易有限公司HLA-A抗体(Abcam, ab52922)被用于被用于免疫组化-石蜡切片在人类样本上浓度为1:250 (图 2c). Int Wound J (2015) ncbi
圣克鲁斯生物技术
小鼠 单克隆(LY5.1)
  • 免疫印迹; 人类; 图 3a
圣克鲁斯生物技术HLA-A抗体(Santa Cruz Biotechnology, sc-52810)被用于被用于免疫印迹在人类样本上 (图 3a). Oncoimmunology (2018) ncbi
小鼠 单克隆
  • 流式细胞仪; 人类; 图 3e, 3f
圣克鲁斯生物技术HLA-A抗体(Santa Cruz, BB7.2)被用于被用于流式细胞仪在人类样本上 (图 3e, 3f). Proc Natl Acad Sci U S A (2016) ncbi
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类; 图 3e, 3f
圣克鲁斯生物技术HLA-A抗体(Santa Cruz, BB7.2)被用于被用于流式细胞仪在人类样本上 (图 3e, 3f). Proc Natl Acad Sci U S A (2016) ncbi
小鼠 单克隆(C-6)
  • 免疫组化; 人类; 1:1300; 图 s6
圣克鲁斯生物技术HLA-A抗体(Santa Cruz Biotechnology, sc-365485)被用于被用于免疫组化在人类样本上浓度为1:1300 (图 s6). Nat Commun (2016) ncbi
小鼠 单克隆(LY5.1)
  • 免疫印迹; 人类; 1:500; 图 2
圣克鲁斯生物技术HLA-A抗体(Santa Cruz Technologies, SC-52810)被用于被用于免疫印迹在人类样本上浓度为1:500 (图 2). Cancer Res (2015) ncbi
小鼠 单克隆(W6/32)
  • 免疫印迹; 人类
圣克鲁斯生物技术HLA-A抗体(Santa Cruz, sc-32235)被用于被用于免疫印迹在人类样本上. J Virol (2015) ncbi
伯乐(Bio-Rad)公司
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类; 图 s8c
伯乐(Bio-Rad)公司HLA-A抗体(AbD Serotec, BB7.2)被用于被用于流式细胞仪在人类样本上 (图 s8c). Science (2016) ncbi
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类; 图 6a
伯乐(Bio-Rad)公司HLA-A抗体(AbD Serotec, BB7.2)被用于被用于流式细胞仪在人类样本上 (图 6a). PLoS ONE (2015) ncbi
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类
伯乐(Bio-Rad)公司HLA-A抗体(Serotec, BB7.2)被用于被用于流式细胞仪在人类样本上. J Immunol (2014) ncbi
西格玛奥德里奇
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类; 图 1a
西格玛奥德里奇HLA-A抗体(Sigma-Aldrich, W6/32)被用于被用于流式细胞仪在人类样本上 (图 1a). Eur J Immunol (2017) ncbi
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类
  • 免疫沉淀; 人类
西格玛奥德里奇HLA-A抗体(Sigma-Aldrich, w6/32)被用于被用于流式细胞仪在人类样本上 和 被用于免疫沉淀在人类样本上. Biochem J (2015) ncbi
安迪生物R&D
小鼠 单克隆(W6/32)
  • 流式细胞仪; 人类
安迪生物R&DHLA-A抗体(R&D Systems, W6/32)被用于被用于流式细胞仪在人类样本上. Clin Cancer Res (2014) ncbi
美天旎
人类 单克隆(REA142)
  • 流式细胞仪; 人类; 图 1d
美天旎HLA-A抗体(Miltenyi-Biotec, REA142)被用于被用于流式细胞仪在人类样本上 (图 1d). Am J Transplant (2017) ncbi
贝克曼库尔特实验系统(苏州)有限公司
小鼠 单克隆(B9.12.1)
  • 流式细胞仪; 人类
贝克曼库尔特实验系统(苏州)有限公司HLA-A抗体(Immunotech, B9.12.1)被用于被用于流式细胞仪在人类样本上. Front Immunol (2019) ncbi
小鼠 单克隆(B9.12.1)
  • 流式细胞仪; 人类; 表 3
贝克曼库尔特实验系统(苏州)有限公司HLA-A抗体(Beckman Coulter (Immunotech), B9.12.1)被用于被用于流式细胞仪在人类样本上 (表 3). Am J Pathol (2017) ncbi
小鼠 单克隆(B9.12.1)
  • 流式细胞仪; 人类; 图 2
贝克曼库尔特实验系统(苏州)有限公司HLA-A抗体(Beckman, B9.12.1)被用于被用于流式细胞仪在人类样本上 (图 2). Sci Rep (2016) ncbi
小鼠 单克隆(B9.12.1)
  • 流式细胞仪; 人类
贝克曼库尔特实验系统(苏州)有限公司HLA-A抗体(Beckman Coulter, B9.12.1)被用于被用于流式细胞仪在人类样本上. Transpl Immunol (2015) ncbi
碧迪BD
小鼠 单克隆(G46-2.6)
  • 流式细胞仪; 人类; 图 s4c
碧迪BDHLA-A抗体(BD, 557348)被用于被用于流式细胞仪在人类样本上 (图 s4c). Stem Cell Reports (2020) ncbi
小鼠 单克隆(G46-2.6)
  • 流式细胞仪; 人类; 图 s4g
碧迪BDHLA-A抗体(BD, 555554)被用于被用于流式细胞仪在人类样本上 (图 s4g). Cell Death Differ (2019) ncbi
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类; 图 2a
碧迪BDHLA-A抗体(BD Biosciences, bb7.2)被用于被用于流式细胞仪在人类样本上 (图 2a). J Exp Med (2018) ncbi
小鼠 单克隆(G46-2.6)
  • 流式细胞仪; 人类; 图 6c
碧迪BDHLA-A抗体(BD Pharmingen, G46-2.6)被用于被用于流式细胞仪在人类样本上 (图 6c). Oncotarget (2017) ncbi
小鼠 单克隆(G46-2.6)
  • 流式细胞仪; 人类; 图 2a
碧迪BDHLA-A抗体(BD Biosciences, 555552)被用于被用于流式细胞仪在人类样本上 (图 2a). Oncotarget (2017) ncbi
小鼠 单克隆(G46-2.6)
  • 抑制或激活实验; 人类; 图 6b
碧迪BDHLA-A抗体(BD Biosciences, G46-2.6)被用于被用于抑制或激活实验在人类样本上 (图 6b). BMC Biotechnol (2017) ncbi
小鼠 单克隆(BB7.2)
  • 抑制或激活实验; 人类; 图 6b
碧迪BDHLA-A抗体(BD Biosciences, BB7.2)被用于被用于抑制或激活实验在人类样本上 (图 6b). BMC Biotechnol (2017) ncbi
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类; 图 6b
碧迪BDHLA-A抗体(BD Biosciences, 551230)被用于被用于流式细胞仪在人类样本上 (图 6b). J Immunol (2016) ncbi
小鼠 单克隆(G46-2.6)
  • 流式细胞仪; 人类; 图 1d
碧迪BDHLA-A抗体(BD Biosciences, G46-2.6)被用于被用于流式细胞仪在人类样本上 (图 1d). J Virol (2016) ncbi
小鼠 单克隆(G46-2.6)
  • 流式细胞仪; 人类
碧迪BDHLA-A抗体(BD PharMingen, 555553)被用于被用于流式细胞仪在人类样本上. Oncoimmunology (2016) ncbi
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类; 图 5d
碧迪BDHLA-A抗体(BD Pharmingen, BB7.2)被用于被用于流式细胞仪在人类样本上 (图 5d). Cytotherapy (2016) ncbi
小鼠 单克隆(G46-2.6)
  • 其他; 人类; 500 ug/ml; 图 1
碧迪BDHLA-A抗体(Becton Dickinson, 555551)被用于被用于其他在人类样本上浓度为500 ug/ml (图 1). J Extracell Vesicles (2016) ncbi
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类; 图 2
碧迪BDHLA-A抗体(BD Biosciences, 551285)被用于被用于流式细胞仪在人类样本上 (图 2). J Clin Invest (2016) ncbi
小鼠 单克隆(G46-2.6)
  • 流式细胞仪; 人类; 图 1
碧迪BDHLA-A抗体(BD Biosciences, 555552)被用于被用于流式细胞仪在人类样本上 (图 1). Int J Mol Med (2016) ncbi
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类; 图 st1
碧迪BDHLA-A抗体(BD, 558570)被用于被用于流式细胞仪在人类样本上 (图 st1). Exp Cell Res (2016) ncbi
小鼠 单克隆(G46-2.6)
  • 流式细胞仪; 人类; 图 2
碧迪BDHLA-A抗体(BD Biosciences, 561346)被用于被用于流式细胞仪在人类样本上 (图 2). Retrovirology (2015) ncbi
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类; 图 s1
碧迪BDHLA-A抗体(BD Biosciences, BB7.2)被用于被用于流式细胞仪在人类样本上 (图 s1). PLoS ONE (2015) ncbi
小鼠 单克隆(G46-2.6)
  • 流式细胞仪; 人类
碧迪BDHLA-A抗体(BD Pharmingen, 555553)被用于被用于流式细胞仪在人类样本上. Cancer Lett (2015) ncbi
小鼠 单克隆(G46-2.6)
  • 免疫组化; 人类; 1:200; 图 1
碧迪BDHLA-A抗体(BD Pharmingen, 555552)被用于被用于免疫组化在人类样本上浓度为1:200 (图 1). Cancer Res (2015) ncbi
小鼠 单克隆(G46-2.6)
  • 流式细胞仪; 人类
碧迪BDHLA-A抗体(BD Biosciences, 555552)被用于被用于流式细胞仪在人类样本上. Nat Genet (2015) ncbi
小鼠 单克隆(G46-2.6)
  • 流式细胞仪; 人类; 表 1
碧迪BDHLA-A抗体(BD Biosciences, G46-2.6)被用于被用于流式细胞仪在人类样本上 (表 1). Cancer Immunol Immunother (2015) ncbi
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类
碧迪BDHLA-A抗体(BD Pharmingen, BB7.2)被用于被用于流式细胞仪在人类样本上. J Virol (2015) ncbi
小鼠 单克隆(BB7.2)
  • 流式细胞仪; 人类
碧迪BDHLA-A抗体(BD Biosciences, BB7.2)被用于被用于流式细胞仪在人类样本上. PLoS ONE (2014) ncbi
小鼠 单克隆(G46-2.6)
  • 流式细胞仪; 人类
碧迪BDHLA-A抗体(BD Biosciences, G46-2.6)被用于被用于流式细胞仪在人类样本上. Blood (2014) ncbi
小鼠 单克隆(G46-2.6)
  • 流式细胞仪; 人类
碧迪BDHLA-A抗体(BD Pharmingen, 555552)被用于被用于流式细胞仪在人类样本上. Urol Oncol (2014) ncbi
小鼠 单克隆(G46-2.6)
  • 流式细胞仪; 人类
碧迪BDHLA-A抗体(BD, 555553)被用于被用于流式细胞仪在人类样本上. Mol Cells (2013) ncbi
小鼠 单克隆(G46-2.6)
  • 流式细胞仪; 人类; 1:200
碧迪BDHLA-A抗体(BD, 555551)被用于被用于流式细胞仪在人类样本上浓度为1:200. PLoS ONE (2013) ncbi
小鼠 单克隆(G46-2.6)
  • 流式细胞仪; 人类; 表 2
碧迪BDHLA-A抗体(BD Pharmingen, 555552)被用于被用于流式细胞仪在人类样本上 (表 2). Cell Transplant (2014) ncbi
小鼠 单克隆(G46-2.6)
  • 流式细胞仪; 人类
碧迪BDHLA-A抗体(BD, 561346)被用于被用于流式细胞仪在人类样本上. PLoS ONE (2012) ncbi
小鼠 单克隆(G46-2.6)
  • 流式细胞仪; 人类; 1:5
碧迪BDHLA-A抗体(BD Pharmingen, G46-2.6)被用于被用于流式细胞仪在人类样本上浓度为1:5. Microvasc Res (2012) ncbi
文章列表
  1. Zurli V, Montecchi T, Heilig R, Poschke I, Volkmar M, Wimmer G, et al. Phosphoproteomics of CD2 signaling reveals AMPK-dependent regulation of lytic granule polarization in cytotoxic T cells. Sci Signal. 2020;13: pubmed 出版商
  2. Yamamoto K, Venida A, Yano J, Biancur D, Kakiuchi M, Gupta S, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature. 2020;581:100-105 pubmed 出版商
  3. Yu K, Lin C, Hatcher A, Lozzi B, Kong K, Huang Hobbs E, et al. PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis. Nature. 2020;578:166-171 pubmed 出版商
  4. Mosaheb M, Dobrikova E, Brown M, Yang Y, Cable J, Okada H, et al. Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity. Nat Commun. 2020;11:524 pubmed 出版商
  5. Queckborner S, Syk Lundberg E, Gemzell Danielsson K, Davies L. Endometrial stromal cells exhibit a distinct phenotypic and immunomodulatory profile. Stem Cell Res Ther. 2020;11:15 pubmed 出版商
  6. Suzuki D, Flahou C, Yoshikawa N, Stirblyte I, Hayashi Y, Sawaguchi A, et al. iPSC-Derived Platelets Depleted of HLA Class I Are Inert to Anti-HLA Class I and Natural Killer Cell Immunity. Stem Cell Reports. 2020;14:49-59 pubmed 出版商
  7. Canon J, Rex K, Saiki A, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575:217-223 pubmed 出版商
  8. Sanz Ortega L, Rojas J, Portilla Y, Pérez Yagüe S, Barber D. Magnetic Nanoparticles Attached to the NK Cell Surface for Tumor Targeting in Adoptive Transfer Therapies Does Not Affect Cellular Effector Functions. Front Immunol. 2019;10:2073 pubmed 出版商
  9. Merola J, Reschke M, Pierce R, Qin L, Spindler S, Baltazar T, et al. Progenitor-derived human endothelial cells evade alloimmunity by CRISPR/Cas9-mediated complete ablation of MHC expression. JCI Insight. 2019;4: pubmed 出版商
  10. Findlay E, Currie A, Zhang A, Ovciarikova J, Young L, Stevens H, et al. Exposure to the antimicrobial peptide LL-37 produces dendritic cells optimized for immunotherapy. Oncoimmunology. 2019;8:1608106 pubmed 出版商
  11. Rosshart S, Herz J, Vassallo B, Hunter A, Wall M, Badger J, et al. Laboratory mice born to wild mice have natural microbiota and model human immune responses. Science. 2019;365: pubmed 出版商
  12. Verma V, Shrimali R, Ahmad S, Dai W, Wang H, Lu S, et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat Immunol. 2019;20:1231-1243 pubmed 出版商
  13. Dangaj D, Bruand M, Grimm A, Ronet C, Barras D, Duttagupta P, et al. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. Cancer Cell. 2019;35:885-900.e10 pubmed 出版商
  14. Sabol R, Bowles A, Côté A, Wise R, O Donnell B, Matossian M, et al. Leptin produced by obesity-altered adipose stem cells promotes metastasis but not tumorigenesis of triple-negative breast cancer in orthotopic xenograft and patient-derived xenograft models. Breast Cancer Res. 2019;21:67 pubmed 出版商
  15. Pavel Dinu M, Wiebking V, Dejene B, Srifa W, Mantri S, Nicolas C, et al. Gene correction for SCID-X1 in long-term hematopoietic stem cells. Nat Commun. 2019;10:1634 pubmed 出版商
  16. Fauster A, Rebsamen M, Willmann K, César Razquin A, Girardi E, Bigenzahn J, et al. Systematic genetic mapping of necroptosis identifies SLC39A7 as modulator of death receptor trafficking. Cell Death Differ. 2019;26:1138-1155 pubmed 出版商
  17. Walwyn Brown K, Guldevall K, Saeed M, Pende D, Önfelt B, MacDonald A, et al. Human NK Cells Lyse Th2-Polarizing Dendritic Cells via NKp30 and DNAM-1. J Immunol. 2018;201:2028-2041 pubmed 出版商
  18. Marijt K, Blijleven L, Verdegaal E, Kester M, Kowalewski D, Rammensee H, et al. Identification of non-mutated neoantigens presented by TAP-deficient tumors. J Exp Med. 2018;215:2325-2337 pubmed 出版商
  19. Nardo G, Trolese M, Verderio M, Mariani A, De Paola M, Riva N, et al. Counteracting roles of MHCI and CD8+ T cells in the peripheral and central nervous system of ALS SOD1G93A mice. Mol Neurodegener. 2018;13:42 pubmed 出版商
  20. Wilson K, Liu H, Healey G, Vuong V, Ishido S, Herold M, et al. MARCH1-mediated ubiquitination of MHC II impacts the MHC I antigen presentation pathway. PLoS ONE. 2018;13:e0200540 pubmed 出版商
  21. Heusinger E, Deppe K, Sette P, Krapp C, Kmiec D, Kluge S, et al. Preadaptation of Simian Immunodeficiency Virus SIVsmm Facilitated Env-Mediated Counteraction of Human Tetherin by Human Immunodeficiency Virus Type 2. J Virol. 2018;92: pubmed 出版商
  22. Luo N, Formisano L, Gonzalez Ericsson P, Sanchez V, Dean P, Opalenik S, et al. Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. Oncoimmunology. 2018;7:e1438106 pubmed 出版商
  23. Zacharakis N, Chinnasamy H, Black M, Xu H, Lu Y, Zheng Z, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 2018;24:724-730 pubmed 出版商
  24. Liao Y, Ivanova L, Sivalenka R, Plumer T, Zhu H, Zhang X, et al. Efficacy of Human Placental-Derived Stem Cells in Collagen VII Knockout (Recessive Dystrophic Epidermolysis Bullosa) Animal Model. Stem Cells Transl Med. 2018;7:530-542 pubmed 出版商
  25. Liu R, Merola J, Manes T, Qin L, Tietjen G, Lopez Giraldez F, et al. Interferon-γ converts human microvascular pericytes into negative regulators of alloimmunity through induction of indoleamine 2,3-dioxygenase 1. JCI Insight. 2018;3: pubmed 出版商
  26. Jung Y, Cackowski F, Yumoto K, Decker A, Wang J, Kim J, et al. CXCL12γ Promotes Metastatic Castration-Resistant Prostate Cancer by Inducing Cancer Stem Cell and Neuroendocrine Phenotypes. Cancer Res. 2018;78:2026-2039 pubmed 出版商
  27. Ende Z, Deymier M, Claiborne D, Prince J, Mónaco D, Kilembe W, et al. HLA Class I Downregulation by HIV-1 Variants from Subtype C Transmission Pairs. J Virol. 2018;92: pubmed 出版商
  28. Barkal A, Weiskopf K, Kao K, Gordon S, Rosental B, Yiu Y, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat Immunol. 2018;19:76-84 pubmed 出版商
  29. Mwimanzi F, Toyoda M, Mahiti M, Mann J, Martin J, Bangsberg D, et al. Resistance of Major Histocompatibility Complex Class B (MHC-B) to Nef-Mediated Downregulation Relative to that of MHC-A Is Conserved among Primate Lentiviruses and Influences Antiviral T Cell Responses in HIV-1-Infected Individuals. J Virol. 2018;92: pubmed 出版商
  30. Shen T, Chen Z, Zhao Z, Wu J. Genetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in the JAK2 gene in non-small cell lung cancer. Oncotarget. 2017;8:60975-60986 pubmed 出版商
  31. Burr M, Sparbier C, Chan Y, Williamson J, Woods K, Beavis P, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549:101-105 pubmed 出版商
  32. Zhang X, Lian X, Dai Z, Zheng H, Chen X, Zheng Y. ?3-Deletion Isoform of HLA-A11 Modulates Cytotoxicity of NK Cells: Correlations with HIV-1 Infection of Cells. J Immunol. 2017;199:2030-2042 pubmed 出版商
  33. Gotsbacher M, Cho S, Kwon H, Karuso P. Daptomycin, a last-resort antibiotic, binds ribosomal protein S19 in humans. Proteome Sci. 2016;15:16 pubmed 出版商
  34. Chang A, Dao T, Gejman R, Jarvis C, Scott A, Dubrovsky L, et al. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. J Clin Invest. 2017;127:2705-2718 pubmed 出版商
  35. Johnson D, Wayt J, Wilson J, Donaldson J. Arf6 and Rab22 mediate T cell conjugate formation by regulating clathrin-independent endosomal membrane trafficking. J Cell Sci. 2017;130:2405-2415 pubmed 出版商
  36. Tong A, Hashem H, Eid S, Allen F, Kingsley D, Huang A. Adoptive natural killer cell therapy is effective in reducing pulmonary metastasis of Ewing sarcoma. Oncoimmunology. 2017;6:e1303586 pubmed 出版商
  37. Seif M, Hoppstädter J, Breinig F, Kiemer A. Yeast-mediated mRNA delivery polarizes immuno-suppressive macrophages towards an immuno-stimulatory phenotype. Eur J Pharm Biopharm. 2017;117:1-13 pubmed 出版商
  38. Cardinaud S, Urrutia A, Rouers A, Coulon P, Kervevan J, Richetta C, et al. Triggering of TLR-3, -4, NOD2, and DC-SIGN reduces viral replication and increases T-cell activation capacity of HIV-infected human dendritic cells. Eur J Immunol. 2017;47:818-829 pubmed 出版商
  39. Ren J, Zhang X, Liu X, Fang C, Jiang S, June C, et al. A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget. 2017;8:17002-17011 pubmed 出版商
  40. Zhu J, Cifuentes H, Reynolds J, Lamba D. Immunosuppression via Loss of IL2rγ Enhances Long-Term Functional Integration of hESC-Derived Photoreceptors in the Mouse Retina. Cell Stem Cell. 2017;20:374-384.e5 pubmed 出版商
  41. Ouisse L, Gautreau Rolland L, Devilder M, Osborn M, Moyon M, Visentin J, et al. Antigen-specific single B cell sorting and expression-cloning from immunoglobulin humanized rats: a rapid and versatile method for the generation of high affinity and discriminative human monoclonal antibodies. BMC Biotechnol. 2017;17:3 pubmed 出版商
  42. Uruha A, Nishikawa A, Tsuburaya R, Hamanaka K, Kuwana M, Watanabe Y, et al. Sarcoplasmic MxA expression: A valuable marker of dermatomyositis. Neurology. 2017;88:493-500 pubmed 出版商
  43. Boardman D, Philippeos C, Fruhwirth G, Ibrahim M, Hannen R, Cooper D, et al. Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection. Am J Transplant. 2017;17:931-943 pubmed 出版商
  44. Fromm J, Thomas A, Wood B. Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting. Am J Pathol. 2017;187:304-317 pubmed 出版商
  45. Kim J, Ko I, Atala A, Yoo J. Progressive Muscle Cell Delivery as a Solution for Volumetric Muscle Defect Repair. Sci Rep. 2016;6:38754 pubmed 出版商
  46. Tomic A, Varanasi P, Golemac M, Malic S, Riese P, Borst E, et al. Activation of Innate and Adaptive Immunity by a Recombinant Human Cytomegalovirus Strain Expressing an NKG2D Ligand. PLoS Pathog. 2016;12:e1006015 pubmed 出版商
  47. Dellgren C, Ekwelum V, Ormhøj M, Pallesen N, Knudsen J, Nehlin J, et al. Low Constitutive Cell Surface Expression of HLA-B Is Caused by a Posttranslational Mechanism Involving Glu180 and Arg239. J Immunol. 2016;197:4807-4816 pubmed
  48. Dever D, Bak R, Reinisch A, Camarena J, Washington G, Nicolas C, et al. CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells. Nature. 2016;539:384-389 pubmed 出版商
  49. Cuff A, Robertson F, Stegmann K, Pallett L, Maini M, Davidson B, et al. Eomeshi NK Cells in Human Liver Are Long-Lived and Do Not Recirculate but Can Be Replenished from the Circulation. J Immunol. 2016;197:4283-4291 pubmed
  50. Albanese M, Tagawa T, Bouvet M, Maliqi L, Lutter D, Hoser J, et al. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells. Proc Natl Acad Sci U S A. 2016;113:E6467-E6475 pubmed
  51. Trautz B, Pierini V, Wombacher R, Stolp B, Chase A, Pizzato M, et al. The Antagonism of HIV-1 Nef to SERINC5 Particle Infectivity Restriction Involves the Counteraction of Virion-Associated Pools of the Restriction Factor. J Virol. 2016;90:10915-10927 pubmed 出版商
  52. Valkenburg K, Amend S, Verdone J, van der Toom E, Hernandez J, Gorin M, et al. A simple selection-free method for detecting disseminated tumor cells (DTCs) in murine bone marrow. Oncotarget. 2016;7:69794-69803 pubmed 出版商
  53. Huang M, Zhang W, Guo J, Wei X, Phiwpan K, Zhang J, et al. Improved Transgenic Mouse Model for Studying HLA Class I Antigen Presentation. Sci Rep. 2016;6:33612 pubmed 出版商
  54. Di Blasio S, Wortel I, van Bladel D, de Vries L, Duiveman de Boer T, Worah K, et al. Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death. Oncoimmunology. 2016;5:e1192739 pubmed 出版商
  55. Tagawa T, Albanese M, Bouvet M, Moosmann A, Mautner J, Heissmeyer V, et al. Epstein-Barr viral miRNAs inhibit antiviral CD4+ T cell responses targeting IL-12 and peptide processing. J Exp Med. 2016;213:2065-80 pubmed 出版商
  56. Saranchova I, Han J, Huang H, Fenninger F, Choi K, Munro L, et al. Discovery of a Metastatic Immune Escape Mechanism Initiated by the Loss of Expression of the Tumour Biomarker Interleukin-33. Sci Rep. 2016;6:30555 pubmed 出版商
  57. Landtwing V, Raykova A, Pezzino G, Beziat V, Marcenaro E, Graf C, et al. Cognate HLA absence in trans diminishes human NK cell education. J Clin Invest. 2016;126:3772-3782 pubmed 出版商
  58. Yamamoto M, Zhao M, Hiroshima Y, Zhang Y, Shurell E, Eilber F, et al. Efficacy of Tumor-Targeting Salmonella A1-R on a Melanoma Patient-Derived Orthotopic Xenograft (PDOX) Nude-Mouse Model. PLoS ONE. 2016;11:e0160882 pubmed 出版商
  59. Sadallah S, Schmied L, Eken C, Charoudeh H, Amicarella F, Schifferli J. Platelet-Derived Ectosomes Reduce NK Cell Function. J Immunol. 2016;197:1663-71 pubmed 出版商
  60. Maglietta A, Maglietta R, Staiano T, Bertoni R, Ancona N, Marra G, et al. The Immune Landscapes of Polypoid and Nonpolypoid Precancerous Colorectal Lesions. PLoS ONE. 2016;11:e0159373 pubmed 出版商
  61. Seif M, Philippi A, Breinig F, Kiemer A, Hoppstädter J. Yeast (Saccharomyces cerevisiae) Polarizes Both M-CSF- and GM-CSF-Differentiated Macrophages Toward an M1-Like Phenotype. Inflammation. 2016;39:1690-703 pubmed 出版商
  62. Terracina K, Graham L, Payne K, Manjili M, Baek A, Damle S, et al. DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer. Cancer Immunol Immunother. 2016;65:1061-73 pubmed 出版商
  63. Zhang R, Miner J, Gorman M, Rausch K, Ramage H, White J, et al. A CRISPR screen defines a signal peptide processing pathway required by flaviviruses. Nature. 2016;535:164-8 pubmed
  64. Liu C, LeClair P, Monajemi M, Sly L, Reid G, Lim C. α-Integrin expression and function modulates presentation of cell surface calreticulin. Cell Death Dis. 2016;7:e2268 pubmed 出版商
  65. Ma Q, Garber H, Lu S, He H, Tallis E, Ding X, et al. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. Cytotherapy. 2016;18:985-94 pubmed 出版商
  66. Reinisch A, Thomas D, Corces M, Zhang X, Gratzinger D, Hong W, et al. A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells. Nat Med. 2016;22:812-21 pubmed 出版商
  67. Strønen E, Toebes M, Kelderman S, van Buuren M, Yang W, van Rooij N, et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science. 2016;352:1337-41 pubmed 出版商
  68. Reches A, Nachmani D, Berhani O, Duev Cohen A, Shreibman D, Ophir Y, et al. HNRNPR Regulates the Expression of Classical and Nonclassical MHC Class I Proteins. J Immunol. 2016;196:4967-76 pubmed 出版商
  69. Göbel K, Pankratz S, Asaridou C, Herrmann A, Bittner S, Merker M, et al. Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells. Nat Commun. 2016;7:11626 pubmed 出版商
  70. Keilhoff G, Lucas B, Uhde K, Fansa H. Selected gene profiles of stressed NSC-34 cells and rat spinal cord following peripheral nerve reconstruction and minocycline treatment. Exp Ther Med. 2016;11:1685-1699 pubmed
  71. Belov L, Matic K, Hallal S, Best O, Mulligan S, Christopherson R. Extensive surface protein profiles of extracellular vesicles from cancer cells may provide diagnostic signatures from blood samples. J Extracell Vesicles. 2016;5:25355 pubmed 出版商
  72. Li H, Borrego F, Nagata S, Tolnay M. Fc Receptor-like 5 Expression Distinguishes Two Distinct Subsets of Human Circulating Tissue-like Memory B Cells. J Immunol. 2016;196:4064-74 pubmed 出版商
  73. Macdonald K, Hoeppli R, Huang Q, Gillies J, Luciani D, Orban P, et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Invest. 2016;126:1413-24 pubmed 出版商
  74. Chung S, Rho S, Kim G, Kim S, Baek K, Kang M, et al. Human umbilical cord blood mononuclear cells and chorionic plate-derived mesenchymal stem cells promote axon survival in a rat model of optic nerve crush injury. Int J Mol Med. 2016;37:1170-80 pubmed 出版商
  75. Apostolidis S, Rodríguez Rodríguez N, Suárez Fueyo A, Dioufa N, Ozcan E, Crispín J, et al. Phosphatase PP2A is requisite for the function of regulatory T cells. Nat Immunol. 2016;17:556-64 pubmed 出版商
  76. Lakschevitz F, Hassanpour S, Rubin A, Fine N, Sun C, Glogauer M. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp Cell Res. 2016;342:200-9 pubmed 出版商
  77. Srivastava P, Paluch B, Matsuzaki J, James S, Collamat Lai G, Blagitko Dorfs N, et al. Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy. Oncotarget. 2016;7:12840-56 pubmed 出版商
  78. Ludigs K, Jandus C, Utzschneider D, Staehli F, Bessoles S, Dang A, et al. NLRC5 shields T lymphocytes from NK-cell-mediated elimination under inflammatory conditions. Nat Commun. 2016;7:10554 pubmed 出版商
  79. Johnson D, Estrada M, Salgado R, Sanchez V, Doxie D, Opalenik S, et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun. 2016;7:10582 pubmed 出版商
  80. Uruha A, Noguchi S, Hayashi Y, Tsuburaya R, Yonekawa T, Nonaka I, et al. Hepatitis C virus infection in inclusion body myositis: A case-control study. Neurology. 2016;86:211-7 pubmed 出版商
  81. Heigele A, Joas S, Regensburger K, Kirchhoff F. Increased susceptibility of CD4+ T cells from elderly individuals to HIV-1 infection and apoptosis is associated with reduced CD4 and enhanced CXCR4 and FAS surface expression levels. Retrovirology. 2015;12:86 pubmed 出版商
  82. Klar A, Gopinadh J, Kleber S, Wadle A, Renner C. Treatment with 5-Aza-2'-Deoxycytidine Induces Expression of NY-ESO-1 and Facilitates Cytotoxic T Lymphocyte-Mediated Tumor Cell Killing. PLoS ONE. 2015;10:e0139221 pubmed 出版商
  83. Thuring C, Follin E, Geironson L, Freyhult E, Junghans V, Harndahl M, et al. HLA class I is most tightly linked to levels of tapasin compared with other antigen-processing proteins in glioblastoma. Br J Cancer. 2015;113:952-62 pubmed 出版商
  84. Fernandez L, Valentin J, Zalacain M, Leung W, Patino Garcia A, Perez Martinez A. Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner. Cancer Lett. 2015;368:54-63 pubmed 出版商
  85. Parkinson M, Piper S, Bright N, Evans J, Boname J, Bowers K, et al. A non-canonical ESCRT pathway, including histidine domain phosphotyrosine phosphatase (HD-PTP), is used for down-regulation of virally ubiquitinated MHC class I. Biochem J. 2015;471:79-88 pubmed 出版商
  86. Li Z, Xu X, Weiss I, Jacobson O, Murphy P. Pre-treatment of allogeneic bone marrow recipients with the CXCR4 antagonist AMD3100 transiently enhances hematopoietic chimerism without promoting donor-specific skin allograft tolerance. Transpl Immunol. 2015;33:125-9 pubmed 出版商
  87. Huygens C, Liénart S, Dedobbeleer O, Stockis J, Gauthy E, Coulie P, et al. Lysosomal-associated Transmembrane Protein 4B (LAPTM4B) Decreases Transforming Growth Factor β1 (TGF-β1) Production in Human Regulatory T Cells. J Biol Chem. 2015;290:20105-16 pubmed 出版商
  88. Herz J, Johnson K, McGavern D. Therapeutic antiviral T cells noncytopathically clear persistently infected microglia after conversion into antigen-presenting cells. J Exp Med. 2015;212:1153-69 pubmed 出版商
  89. Yawata N, Selva K, Liu Y, Tan K, Lee A, Siak J, et al. Dynamic change in natural killer cell type in the human ocular mucosa in situ as means of immune evasion by adenovirus infection. Mucosal Immunol. 2016;9:159-70 pubmed 出版商
  90. Miranda A, Funes J, Sánchez N, Limia C, Mesa M, Quezada S, et al. Oncogenic Transformation Can Orchestrate Immune Evasion and Inflammation in Human Mesenchymal Stem Cells Independently of Extrinsic Immune-Selective Pressure. Cancer Res. 2015;75:3032-42 pubmed 出版商
  91. Rancan C, Schirrmann L, Hüls C, Zeidler R, Moosmann A. Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells. PLoS Pathog. 2015;11:e1004906 pubmed 出版商
  92. Guo X, Liu T, Shi H, Wang J, Ji P, Wang H, et al. Respiratory Syncytial Virus Infection Upregulates NLRC5 and Major Histocompatibility Complex Class I Expression through RIG-I Induction in Airway Epithelial Cells. J Virol. 2015;89:7636-45 pubmed 出版商
  93. Maass P, Aydin A, Luft F, Schächterle C, Weise A, Stricker S, et al. PDE3A mutations cause autosomal dominant hypertension with brachydactyly. Nat Genet. 2015;47:647-53 pubmed 出版商
  94. Tang B, Zhou W, Du J, He Y, Li Y. Identification of human leukemia antigen A*0201-restricted epitopes derived from epidermal growth factor pathway substrate number 8. Mol Med Rep. 2015;12:1741-52 pubmed 出版商
  95. Walseng E, Wälchli S, Fallang L, Yang W, Vefferstad A, Areffard A, et al. Soluble T-cell receptors produced in human cells for targeted delivery. PLoS ONE. 2015;10:e0119559 pubmed 出版商
  96. Jørgensen M, Bæk R, Varming K. Potentials and capabilities of the Extracellular Vesicle (EV) Array. J Extracell Vesicles. 2015;4:26048 pubmed 出版商
  97. Boerman G, van Ostaijen Ten Dam M, Kraal K, Santos S, Ball L, Lankester A, et al. Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells. Cancer Immunol Immunother. 2015;64:573-83 pubmed 出版商
  98. Cheah M, Chen J, Sahoo D, Contreras Trujillo H, Volkmer A, Scheeren F, et al. CD14-expressing cancer cells establish the inflammatory and proliferative tumor microenvironment in bladder cancer. Proc Natl Acad Sci U S A. 2015;112:4725-30 pubmed 出版商
  99. Bradley S, Chen Z, Melendez B, Talukder A, Khalili J, Rodríguez Cruz T, et al. BRAFV600E Co-opts a Conserved MHC Class I Internalization Pathway to Diminish Antigen Presentation and CD8+ T-cell Recognition of Melanoma. Cancer Immunol Res. 2015;3:602-9 pubmed 出版商
  100. Nambiar J, Clarke A, Shim D, Mabon D, Tian C, Windloch K, et al. Potent neutralizing anti-CD1d antibody reduces lung cytokine release in primate asthma model. MAbs. 2015;7:638-50 pubmed 出版商
  101. Tomimaru Y, Mishra S, Safran H, Charpentier K, Martin W, De Groot A, et al. Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma. Vaccine. 2015;33:1256-66 pubmed 出版商
  102. Khan A, Srivastava R, Spencer D, Garg S, Fremgen D, Vahed H, et al. Phenotypic and functional characterization of herpes simplex virus glycoprotein B epitope-specific effector and memory CD8+ T cells from symptomatic and asymptomatic individuals with ocular herpes. J Virol. 2015;89:3776-92 pubmed 出版商
  103. Esquivel E, Maeda A, Eguchi H, Asada M, Sugiyama M, Manabe C, et al. Suppression of human macrophage-mediated cytotoxicity by transgenic swine endothelial cell expression of HLA-G. Transpl Immunol. 2015;32:109-15 pubmed 出版商
  104. de Carvalho J, de Castro R, da Silva E, Silveira P, da Silva Januário M, Arruda E, et al. Nef neutralizes the ability of exosomes from CD4+ T cells to act as decoys during HIV-1 infection. PLoS ONE. 2014;9:e113691 pubmed 出版商
  105. Boltjes A, van Montfoort N, Biesta P, Op den Brouw M, Kwekkeboom J, van der Laan L, et al. Kupffer cells interact with hepatitis B surface antigen in vivo and in vitro, leading to proinflammatory cytokine production and natural killer cell function. J Infect Dis. 2015;211:1268-78 pubmed 出版商
  106. Matheson N, Peden A, Lehner P. Antibody-free magnetic cell sorting of genetically modified primary human CD4+ T cells by one-step streptavidin affinity purification. PLoS ONE. 2014;9:e111437 pubmed 出版商
  107. Srivastava P, Paluch B, Matsuzaki J, James S, Collamat Lai G, Karbach J, et al. Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. Leuk Res. 2014;38:1332-41 pubmed 出版商
  108. Abramowski P, Ogrodowczyk C, Martin R, Pongs O. A truncation variant of the cation channel P2RX5 is upregulated during T cell activation. PLoS ONE. 2014;9:e104692 pubmed 出版商
  109. Chao Y, Kaliaperumal N, Chretien A, Tang S, Lee B, Poidinger M, et al. Human plasmacytoid dendritic cells regulate IFN-α production through activation-induced splicing of IL-18Rα. J Leukoc Biol. 2014;96:1037-46 pubmed 出版商
  110. Davey M, Morgan M, Liuzzi A, Tyler C, Khan M, Szakmany T, et al. Microbe-specific unconventional T cells induce human neutrophil differentiation into antigen cross-presenting cells. J Immunol. 2014;193:3704-3716 pubmed 出版商
  111. Jung Y, Wang J, Lee E, McGee S, Berry J, Yumoto K, et al. Annexin 2-CXCL12 interactions regulate metastatic cell targeting and growth in the bone marrow. Mol Cancer Res. 2015;13:197-207 pubmed 出版商
  112. Arellano Garcia M, Misuno K, Tran S, Hu S. Interferon-? induces immunoproteasomes and the presentation of MHC I-associated peptides on human salivary gland cells. PLoS ONE. 2014;9:e102878 pubmed 出版商
  113. Koido S, Homma S, Okamoto M, Takakura K, Mori M, Yoshizaki S, et al. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer. Clin Cancer Res. 2014;20:4228-39 pubmed 出版商
  114. Lee Chang C, Bodogai M, Moritoh K, Olkhanud P, Chan A, Croft M, et al. Accumulation of 4-1BBL+ B cells in the elderly induces the generation of granzyme-B+ CD8+ T cells with potential antitumor activity. Blood. 2014;124:1450-9 pubmed 出版商
  115. Ameres S, Besold K, Plachter B, Moosmann A. CD8 T cell-evasive functions of human cytomegalovirus display pervasive MHC allele specificity, complementarity, and cooperativity. J Immunol. 2014;192:5894-905 pubmed 出版商
  116. Hofner T, Macher Goeppinger S, Klein C, Schillert A, Eisen C, Wagner S, et al. Expression and prognostic significance of cancer stem cell markers CD24 and CD44 in urothelial bladder cancer xenografts and patients undergoing radical cystectomy. Urol Oncol. 2014;32:678-86 pubmed 出版商
  117. Kang W, Sung P, Park S, Yoon S, Chang D, Kim S, et al. Hepatitis C virus attenuates interferon-induced major histocompatibility complex class I expression and decreases CD8+ T cell effector functions. Gastroenterology. 2014;146:1351-60.e1-4 pubmed 出版商
  118. Stahlschmidt W, Robertson M, Robinson P, McCluskey A, Haucke V. Clathrin terminal domain-ligand interactions regulate sorting of mannose 6-phosphate receptors mediated by AP-1 and GGA adaptors. J Biol Chem. 2014;289:4906-18 pubmed 出版商
  119. Shanmugam V, Tassi E, Schmidt M, McNish S, Baker S, Attinger C, et al. Utility of a human-mouse xenograft model and in vivo near-infrared fluorescent imaging for studying wound healing. Int Wound J. 2015;12:699-705 pubmed 出版商
  120. Han J, Rho S, Lee J, Bae J, Park S, Lee S, et al. Human cytomegalovirus (HCMV) US2 protein interacts with human CD1d (hCD1d) and down-regulates invariant NKT (iNKT) cell activity. Mol Cells. 2013;36:455-64 pubmed 出版商
  121. Fuentes T, Appleby N, Tsay E, Martinez J, Bailey L, Hasaniya N, et al. Human neonatal cardiovascular progenitors: unlocking the secret to regenerative ability. PLoS ONE. 2013;8:e77464 pubmed 出版商
  122. Svajger U, Obermajer N, Jeras M. IFN-?-rich environment programs dendritic cells toward silencing of cytotoxic immune responses. J Leukoc Biol. 2014;95:33-46 pubmed 出版商
  123. Zuliani T, Saiagh S, Knol A, Esbelin J, Dreno B. Fetal fibroblasts and keratinocytes with immunosuppressive properties for allogeneic cell-based wound therapy. PLoS ONE. 2013;8:e70408 pubmed 出版商
  124. Jacobs S, Plessers J, Pinxteren J, Roobrouck V, Verfaillie C, Van Gool S. Mutual interaction between human multipotent adult progenitor cells and NK cells. Cell Transplant. 2014;23:1099-110 pubmed 出版商
  125. Gaur R, Suhosk M, Banaei N. In vitro immunomodulation of a whole blood IFN-? release assay enhances T cell responses in subjects with latent tuberculosis infection. PLoS ONE. 2012;7:e48027 pubmed 出版商
  126. Sölder E, Böckle B, Nguyen V, Fürhapter C, Obexer P, Erdel M, et al. Isolation and characterization of CD133+CD34+VEGFR-2+CD45- fetal endothelial cells from human term placenta. Microvasc Res. 2012;84:65-73 pubmed 出版商
  127. Schneider C, Hudson A. The human herpesvirus-7 (HHV-7) U21 immunoevasin subverts NK-mediated cytoxicity through modulation of MICA and MICB. PLoS Pathog. 2011;7:e1002362 pubmed 出版商
  128. Di Pucchio T, Chatterjee B, Smed Sorensen A, Clayton S, Palazzo A, Montes M, et al. Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat Immunol. 2008;9:551-7 pubmed 出版商